CYP17A1 and prostate carcinoma: AA is a highly selective and irreversible CYP17 inhibitor of androgen synthesis in the prostate cancer cells, adrenal glands, and testicles, and acts by suppressing CYP17 (the key enzyme in the androgen synthesis pathway).